Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 19, Issue 1

January-February 2022

In this Issue

Ask the Hematopathologists
Features
Headlines from Washington
President's Column
Year’s Best

Ask the Hematopathologists

Germline Disease in Older Patients: The Case for Vigilance

Zaynab Al-Duwal, MD,Ashley Cunningham, MD

View Articletitled, Germline Disease in Older Patients: The Case for Vigilance

Features

Reliving #ASH21: The Historic 63rd ASH Annual Meeting

Naseema Gangat, MBBS

View Articletitled, Reliving #ASH21: The Historic 63rd ASH Annual Meeting

Headlines from Washington

A Look Back at 2021 Shows a Year Full of Creative Advocacy

ASH Staff

View Articletitled, A Look Back at 2021 Shows a Year Full of Creative Advocacy

President's Column

Science Versus the Rising Tide of Distrust

Jane N. Winter, MD

View Articletitled, Science Versus the Rising Tide of Distrust

Year’s Best

Oral Maintenance Therapy to Improve Survival in Older Patients With AML

Nathan Klose, MBBS, FRACP,Steven Lane, MBBS, PhD, FRACP, FRCPA

View Articletitled, Oral Maintenance Therapy to Improve Survival in Older Patients With AML

Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-“sights” Set on Becoming Standard of Care

Frederick L. Locke, MD

View Articletitled, Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-“sights” Set on Becoming Standard of Care

Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future

Amy DeZern, MD, MHS

View Articletitled, Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future

From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia

Kristen M. O'Dwyer, MD

View Articletitled, From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia

The 2021 Year’s Best

Laura C. Michaelis, MD

View Articletitled, The 2021 Year’s Best

Emerging Evidence for Old Drugs (Mycophenolate) and New Ones (Fostamatinib) in the Treatment of Immune Thrombocytopenia

Eric Tseng, MD, MScCH, FRCPC

View Articletitled, Emerging Evidence for Old Drugs (Mycophenolate) and New Ones (Fostamatinib) in the Treatment of Immune Thrombocytopenia

Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials

Damon Houghton, MD

View Articletitled, Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials

iStopMM: A Monumental Effort

Malin Hultcrantz, MD, PhD,Saad Usmani, MD, MBA, FACP

View Articletitled, iStopMM: A Monumental Effort

Chronic Lymphocytic Leukemia and a Pandemic: A Bad Combination

Brad Kahl, MD

View Articletitled, Chronic Lymphocytic Leukemia and a Pandemic: A Bad Combination

Combinatorial BCL-2 Inhibition for ALL of the Leukemias: The Sum Is More Than the Parts

Sarah K. Tasian, MD

View Articletitled, Combinatorial BCL-2 Inhibition for ALL of the Leukemias: The Sum Is More Than the Parts

How a Call to Action Will Revolutionize Sickle Cell Disease

Ahmar U. Zaidi, MD,Caterina P. Minniti, MD,Ifeyinwa (Ify) Osunkwo, MD, MPH

View Articletitled, How a Call to Action Will Revolutionize Sickle Cell Disease

Inflammatory Crosstalk Drives Clonal Hematopoiesis

Adam Mead, MD, PhD

View Articletitled, Inflammatory Crosstalk Drives Clonal Hematopoiesis

This Year’s Best in Hematology Diagnosis: A New Disease Is Discovered

Robert P. Hasserjian, MD

View Articletitled, This Year’s Best in Hematology Diagnosis: A New Disease Is Discovered

Cover Image

Cover Image

All Issues

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Restoring T-cell Cytotoxicity To Correct Familial Hemophagocytic Lymphohistiocytosis

Not So Benign
This Is Not Your Father’s Thrombotic Thrombocytopenic Purpura

Perspective
Procedure Skills in Hematology Training: Lost Cause or Worth Fighting For?

ASH Committees Visit Capitol Hill in Support of Funding

Table of Contents

Ask the Hematopathologists

Germline Disease in Older Patients: The Case for Vigilance

Features

Reliving #ASH21: The Historic 63rd ASH Annual Meeting

Headlines from Washington

A Look Back at 2021 Shows a Year Full of Creative Advocacy

President's Column

Science Versus the Rising Tide of Distrust

Year’s Best

Oral Maintenance Therapy to Improve Survival in Older Patients With AML

Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-“sights” Set on Becoming Standard of Care

Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future

From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia

The 2021 Year’s Best

Emerging Evidence for Old Drugs (Mycophenolate) and New Ones (Fostamatinib) in the Treatment of Immune Thrombocytopenia

Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials

iStopMM: A Monumental Effort

Chronic Lymphocytic Leukemia and a Pandemic: A Bad Combination

Combinatorial BCL-2 Inhibition for ALL of the Leukemias: The Sum Is More Than the Parts

How a Call to Action Will Revolutionize Sickle Cell Disease

Inflammatory Crosstalk Drives Clonal Hematopoiesis

This Year’s Best in Hematology Diagnosis: A New Disease Is Discovered

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Ask the Hematopathologists

Features

Headlines from Washington

President's Column

Year’s Best

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only